Yes, she can safely take both doxycycline and polymyxin B eye drops while on Orserdu (elacestrant).
There are no documented drug interactions between Orserdu and either doxycycline or polymyxin B ophthalmic drops, and these medications can be used concurrently.
Drug Interaction Analysis
Orserdu (Elacestrant) Metabolism
Orserdu is primarily metabolized by CYP3A4 in the liver 1. The FDA label specifically warns about interactions with strong CYP3A4 inhibitors and inducers (such as itraconazole and rifampin), but neither doxycycline nor polymyxin B ophthalmic drops fall into these categories 1.
Doxycycline Considerations
- Systemic absorption from oral doxycycline does not involve CYP3A4 metabolism in a clinically significant way
- Doxycycline is commonly used for various infections including conjunctivitis, blepharitis, and chlamydial infections 2, 3, 4
- The standard adult dose is 100 mg orally twice daily for 7 days 3
- No contraindication exists for concurrent use with elacestrant
Polymyxin B Ophthalmic Drops
- Topical ophthalmic polymyxin B has minimal to negligible systemic absorption when applied to the eye
- It is commonly combined with other antibiotics (neomycin, dexamethasone) in ophthalmic formulations 5, 6
- No systemic drug interactions are expected with oral oncologic agents like Orserdu
Clinical Context
The Orserdu FDA label instructs patients to "inform their healthcare providers of all concomitant medications, including prescription medicines, over-the-counter drugs, and herbal products" 1, but this is standard precautionary language rather than indication of specific interactions with antibiotics or topical ophthalmic agents.
Practical Recommendations
For oral doxycycline:
- Take with 8 ounces of fluid to reduce esophageal irritation 7
- Take with food to reduce gastrointestinal intolerance 7
- Avoid excessive sun exposure due to photosensitivity risk 7
- Continue Orserdu at the same time each day with food as prescribed 1
For polymyxin B eye drops:
- Apply as directed (typically in combination products)
- No timing restrictions relative to Orserdu administration
- Monitor for local ocular reactions (rare with polymyxin B alone)
Important Caveat
While the 60-year-old patient is postmenopausal (as Orserdu is indicated for postmenopausal women with ER+/HER2- breast cancer 1), ensure she is not pregnant, as doxycycline is contraindicated in pregnancy 2, 3, 7. However, given her age and Orserdu indication, this is unlikely to be a concern.